ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Oncology"

  • Abstract Number: 1158 • ACR Convergence 2024

    Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients

    Sehreen Mumtaz1, Megan Sullivan2, Maximiliano Diaz Menindez3, Emily Craver4 and Florentina Berianu5, 1Mayo Clinic, Florida, Jacksonville, FL, 2Mayo Clinic Arizona, Scottsdale, AZ, 3Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, 4Mayo Clinic Florida, Jacksonville, FL, 5mayo clinic, Ponte Vedra Beach, FL

    Background/Purpose: Nailfold videocapillaroscopy (NVC) findings have been studied to differ in different subsets of myositis-specific autoantibodies (MSAs) associated inflammatory myopathies. Prior investigations observed a statistically…
  • Abstract Number: 1327 • ACR Convergence 2024

    Association of Rheumatoid Arthritis and Frailty Status with Mortality in Patients with Renal Cell Carcinoma

    Sherwin Novin1, Sarah Holt2, Maya Swaminathan3, Jonathan Wright2, John Gore2, Kimme Hyrich4, Sizheng Zhao5, Jeffrey Sparks6, Una Makris7, Maria Suarez-Almazor8, Petros Grivas2, Sarah Psutka2 and Namrata Singh9, 1University of Washington, Seattle, WA, 2University of Washington, Seattle, 3MultiCare, Newcastle, WA, 4Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 5Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 7UT Southwestern Medical Center and Dallas VA, Dallas, TX, 8MD Anderson Cancer Center, Houston, TX, 9University of Washington, Bellevue, WA

    Background/Purpose: Few studies have evaluated clinical outcomes and prognosis of patients with cancer with and without rheumatoid arthritis (RA). Renal cell carcinoma (RCC) is particularly…
  • Abstract Number: 1353 • ACR Convergence 2024

    Association Between Frailty and Incident Cancer in Newly Diagnosed Rheumatoid Arthritis

    Bhavik Bansal1, Laura Gold2, Katherine Wysham3, James Andrews4, Alexa Meara5, Carolyn Presley6, Elad Sharon7, Jiha Lee8, Jennifer Barton9, Una Makris10 and Namrata Singh11, 1All India Institute of Medical Sciences, New Delhi, Delhi, India, 2University of Washington, Seattle, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Alabama at Birmingham, Birmingham, AL, 5The Ohio State University Wexner Medical Center, COLUMBUS, OH, 6The Ohio State Medical Center, Columbus, OH, 7Dana Farber Cancer Institute, Boston, MA, 8University of Michigan, Ann Arbor, MI, 9VA Portland Health Care System/OHSU, Portland, OR, 10UT Southwestern Medical Center and Dallas VA, Dallas, TX, 11University of Washington, Bellevue, WA

    Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of cancer, but the underlying risk factors remain poorly understood. Frailty is linked to an…
  • Abstract Number: 1374 • ACR Convergence 2024

    Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer

    Roba Ghossan1, Elodie Portier2, OLIVIER FOGEL3, Sophie Hecquet1, Astrid Dauchez1, Omar AL TABAA4, Marion THOMAS5, Julia Herrou1, Yannick Allanore6 and Jérôme Avouac7, 1COCHIN HOSPITAL, PARIS, France, 2Cochin Hospital, Bry sur Marne, France, 3AP-HP, Paris, France, 4APHP - Cochin Hospital, Paris, France, 5APHP, Paris, France, 6Université Paris Cité, Paris, France, 7Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France

    Background/Purpose: Managing inflammatory arthritis patients on biologics with a history of cancer remains a complex task in daily rheumatology practice and requires a thoughtful, individualized…
  • Abstract Number: 1400 • ACR Convergence 2024

    Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer

    Varun Nandakumar1, Aaron Baraff2, Alexander Peterson2, Nicholas Smith3, Jennifer Barton4, Ann O'Hare2, Christopher Li5, Noel Weiss3 and Namrata Singh6, 1AIIMS, New Delhi, Delhi, India, 2VA PUGET SOUND SEATTLE, Seattle, WA, 3University of Washington, Seattle, WA, 4VA Portland Health Care System/OHSU, Portland, OR, 5University of Washington, Seattle, 6University of Washington, Bellevue, WA

    Background/Purpose: Despite the significant therapeutic benefits of various disease modifying anti-rheumatic drugs (DMARDs) in RA, concerns remain regarding their safety, particularly their potential impact on…
  • Abstract Number: 1726 • ACR Convergence 2024

    Safety, Cancer Progression, and Autoimmune Disease Activity in Patients with Pre-Existing Autoimmune Disease Undergoing CD19 CAR T Cell Therapy for Lymphoma: A Retrospective Comparative Cohort Study

    Kathleen Vanni1, Kaitlin McCarter1, Xiaosong Wang2, Caitlyn Duffy3, Jamie Dela Cruz3, Holly Wobma4, Sarah Nikiforow3, Elena Massarotti1, Karen Costenbader5, Jessica Little1, Ellen Gravallese6, Gregory McDermott7, Caron Jacobson3 and Jeffrey Sparks8, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women’s Hospital, Boston, MA, 3Dana Farber Cancer Institute, Boston, MA, 4Division of Immunology, Boston Children's Hospital, Boston, MA, 5Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, 6Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, 7Brigham and Women's Hospital, Brookline, MA, 8Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: CD19-targeted chimeric antigen receptor (CAR) T cell therapy is FDA-approved to treat lymphoma. A recent prospective case series of CD19 CAR T cell therapy…
  • Abstract Number: 2512 • ACR Convergence 2023

    Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis

    Jacques-Eric Gottenberg1, Nathanaël Sedmak2, Pierre Tran Ba Loc2, Thibaut Fabacher2, Thibaut Bahougne2, Cécile Arnold2, Guillaume Desjeux3, Hervé Servy4, Nicolas Meyer2, Erik Sauleau2, Raphaele Seror5 and Eden Sebbag6, 1Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, 2Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 3e-Health Services Sanoia, Gemenos, France, 4e-Health Services Sanoia, La Ciotat, France, 5University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 6Université de Strasbourg, Strasbourg, France

    Background/Purpose: In about 10% of patients, the immune response to immune checkpoint inhibitors (ICI) exceeds the anti-tumor response and leads to autoimmune complications (immune-related Adverse…
  • Abstract Number: 2513 • ACR Convergence 2023

    Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

    Laura Cappelli1, Jamie Perin2, Clifton Bingham3 and Ami Shah4, 1Johns Hopkins School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD, 4Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD

    Background/Purpose: : Immune checkpoint inhibitors (ICI) for cancer treatment can cause inflammatory arthritis (IA). ICI-IA is a heterogeneous entity affecting peripheral joints, tendons, and rarely…
  • Abstract Number: 2514 • ACR Convergence 2023

    Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis

    Selene Rubino1, Grant Cannon2, Brian Sauer3, Jorge Rojas Jr4, Greg Stoddard1, Gary Kunkel1, Jessica A Walsh5, Bryant England6, Ted R Mikuls7, Joshua Baker8 and Tawnie Braaten1, 1University of Utah, Salt Lake City, UT, 2University of Utah and Salt Lake City VA, Salt Lake City, UT, 3Salt Lake City VA/University of Utah, Salt Lake City, UT, 4Puget Sound VA and University of Utah, Seattle, WA, 5Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, 6University of Nebraska Medical Center, Omaha, NE, 7Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Myositis is an infrequent but serious complication associated with immune check point inhibitor (ICI) treatment. Many patients with ICI-induced myositis will develop concurrent myocarditis…
  • Abstract Number: 0016 • ACR Convergence 2023

    Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts

    Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA

    Background/Purpose: TP53, a tumor-suppressor protein known as the guardian of the genome, plays a critical role in regulating genomic stability and cellular function. When TP53…
  • Abstract Number: 0072 • ACR Convergence 2023

    Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons

    Marie Naingeon1, Samuel Bitoun2, Matthieu roulleaux Dugage1, Caroline de Oliveira1, Caroline Berthot1, Xavier Mariette3, Nathalie Chaput1 and Gaetane Nocturne4, 1LIO, Department of Medicine, Gustave Roussy Université Paris Saclay, Villejuif, France, 2CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, 3Université Paris-Saclay, Le Kremlin-Bicêtre, France, 4APHP, Le Kremlin-Bicêtre, France

    Background/Purpose: Immunosenescence is a global remodeling of immune functions that has been first described with aging. It can also occur in pathologies associated with chronic…
  • Abstract Number: 0125 • ACR Convergence 2023

    Decreasing Ischemic Heart Disease, but Increasing Cancer Among the Underlying Causes of Death in Decedents with Lupus Nephritis

    snehin Rajkumar1 and Ram Singh2, 1University of California Los Angeles, Irvine, CA, 2UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Patients with lupus nephritis may die of active systemic lupus erythematosus (SLE) disease, end-stage renal disease (ESRD) and its complications as well as of…
  • Abstract Number: 1054 • ACR Convergence 2023

    Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT

    David Liew1, Aurora Poon1, Christopher McMaster2, Russell Buchanan1, Victor Yang1, Andrew Scott1 and Claire Owen3, 1Austin Health, Heidelberg, Australia, 2Austin Health, Pascoe Vale South, Australia, 3Austin Health, Malvern East, Australia

    Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…
  • Abstract Number: 1056 • ACR Convergence 2023

    Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study

    Alexandra Ladouceur1, Gael Mouterde2, Alice TISON3, Samuel Bitoun4, Sorilla Mary-Prey5, Caroline Dutriaux6, Emilie Gerard5, Anne Pham-Ledard5, Marie Beylot-Barry5, Maeva Zysman5, Rémi Veillon5, Charlotte Domblides7, Amaury Daste7, Marine Gross-Goupil7, Baptiste Sionneau7, Félix Lefort7, Mathieu Larroquette7, Thomas Barnetche8, Christophe Richez9, Marie-Elise Truchetet8, Thierry Schaeverbebke10 and Marie Kostine8, 1Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, 2CHU Lapeyronie, Montpellier, France, 3CHU de la Cavale Blanche, Brest, France, 4Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184, Paris, France, 5Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, 6CHU-Bordeaux, Bordeaux, France, 7Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, 8Bordeaux University Hospital, Bordeaux, France, 9Université de Bordeaux, Bordeaux, France, 10University Hospital of Bordeaux, Bordeaux, France

    Background/Purpose: Immune checkpoint inhibitors (ICI) improve overall survival in many cancer patients by activating their immune system. However, they can cause off-target immune-related adverse events…
  • Abstract Number: 1057 • ACR Convergence 2023

    Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data

    Alexandra Ladouceur1, Marie Hudson2, Hassan Behlouli3, Jeffrey Curtis4, Louise Pilote3 and Sasha Bernatsky3, 1Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, 2McGill University, Montréal, QC, Canada, 3Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Immune checkpoint inhibitors (ICIs) improve survival in many malignancies1, by augmenting the immune system's anti-tumor response. However, ICI can result in immune-related adverse events…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology